Invea Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Invea Therapeutics, Inc. - overview
Established
2021
Location
Guilford, CT, US
Primary Industry
Biotechnology
About
Based in Connecticut, US, and founded in 2021, Invea Therapeutics, Inc. is a biotechnology company that develops medicines designed for immune-mediated inflammatory disorders (IMIDs). The company was founded by its CEO and president, Krishnan Nandabalan. In April 2022, Invea Therapeutics, Inc.
raised USD 1. 53 million in venture funding from Connecticut Innovations. The company develops precision medicines for individuals suffering from gastrointestinal and hepatobiliary disorders. The firm employs AI to decode the intricate relationship known as the gut-brain axis (GBA) that integrates various types of data, encompassing biology, symptomatology, and pharmacology.
Invea's focus on innate immunity, inflammasome biology, and neuroinflammation provides a precision medicine approach to address the root causes of disorders affected by the GBA. The company’s pipeline programs include INVA8001, INVA8002, INVA8003, and the discovery pipeline. The organization intends to go public on the Nasdaq (INAI).
Current Investors
Connecticut Innovations
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Healthcare IT, Pharmaceutical Research & Development
Verticals
Artificial Intelligence
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.